Clinical Trials

Phase I/II trial of anti-PD-1 checkpoint inhibitor nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients with Extensive-Stage Small Cell Lung Cancer


Study ID
Georgetown CA209-9D6 (PRRIT)

NCT Number
NCT03325816 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0817

Principle Investigator
Dr. Martin Gutierrez

Phase
I/II

Sponsor
Georgetown University


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now